Clinical Trial VICCHEM12107


A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)

Principal Investigator(s)

Madan Jagasia


  • Protocol No. VICCHEM12107
  • Open Date: 03/31/2013
  • Staging: Phase III
  • Age Group: Adults
  • Scope: National
  • Objective: To compare the efficacy and safety of POM + BTZ + LD-DEX with BTZ + LD-DEX in subjects with relapsed or refractory MM
  • Disease Sites: Multiple Myeloma
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Bortezomib (BTZ); Dexamethasone; Pomalidomide (POM)(CC-4047); VELCADE
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01734928
  • Secondary Protocol No: CC-4047-MM-007



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.